Skip to main content

Immunology

Dr. John Cush
@RheumNow
Check the genetics in your patients with ILD A common misconception is that genetic variants don’t cause disease in adults, says Dr. Korf. According to Dr. Bogunovic, 1 in 4 adults will have a first manifestation of genetic error of immunity in adulthood. Genetics seems to be https://t.co/qRUV0oiu0a
Dr. John Cush
@RheumNow
T-Cell Engagers in Autoimmunity: CRS From 12% to 67% Across Six Reports Six ACR 2026 reports put BCMA, CD19, CD20 and gamma-delta engagers side by side in autoimmune disease. The efficacy signal is consistent. The safety signal depends almost entirely on how the molecule was https://t.co/PHm1fF3Tg4
Dr. John Cush
@RheumNow
CAR T Gets the Spotlight. Are We Missing the B Cells That Matter? CAR T is having its moment in rheumatology. But William Robinson’s presentation at ACR Convergence 2026 raised a question I find even more compelling: are we failing to eliminate the right B cells with therapies https://t.co/uta77oaayo
Dr. John Cush
@RheumNow
One Diagnosis, Different Diseases: Is TLR7/8 Inhibition the Future of Lupus Treatment? We call it systemic lupus erythematosus (SLE), but are we really treating one disease? Increasingly, I wonder whether grouping biologically distinct patients under one diagnosis is limiting https://t.co/EkudaG7YiY
Dr. John Cush
@RheumNow
Pre-RA: Antibodies Sort the Risk, Ultrasound Erosions Flag Severity Three ACR 2026 abstracts from the Leeds CCP cohort tested how to triage anti-CCP positive individuals with musculoskeletal symptoms. Serology and a few clinical items carried the prediction, while ultrasound https://t.co/91HG7xPS3o
Dr. John Cush
@RheumNow
Efgartigimod: A New Mechanism for Myositis? Abstracts come and go, but new trials and new mechanisms stay with us for the long haul. One of the more interesting new mechanisms is the FcRn drugs, and at ACR Convergence 2026 we got to see positive results from the Phase 3 ALKIVIA https://t.co/cCgItPQSPS
Dr. John Cush
@RheumNow
Pregnancy After CAR-T in Autoimmune Disease: 14 Pregnancies, No Flares The first multicenter series of pregnancies after CAR T-cell therapy for autoimmune disease reports 8 healthy births and no maternal flares. It is the first dataset of its kind, and the numbers are small. https://t.co/uqWz8GeAmX
Dr. John Cush
@RheumNow
One Diagnosis, Different Diseases: Is TLR7/8 Inhibition the Future of Lupus Treatment? We call it systemic lupus erythematosus (SLE), but are we really treating one disease? Increasingly, I wonder whether grouping biologically distinct patients under one diagnosis is limiting https://t.co/30MGwIRUgO
Dr. John Cush
@RheumNow
Beyond Joint Inflammation: Does Early RA Control Prevent Chronic Pain and Fatigue? Could the therapeutic window of opportunity in rheumatoid arthritis extend beyond preventing structural damage to preventing chronic pain, fatigue, and neuroimmune complications? This is the https://t.co/WVSjwIHOAM
Antoni Chan MD (Prof)
@synovialjoints
ACR26 summary, gut joint axis: replenishing TRBV9 CD8 T cells, a dual targeting antibody, calprotectin for gut inflammation, and outcomes of joint gastroenterology and rheumatology meetings. @rheumnow #ACR26 Abstract#1027 Abstract#2941 Abstract#1336 Abstract#2287
anita
@docdhanrajani

@RheumNow #3. Abstract 0041. Can CAR-T therapy truly “reset” the immune system in lupus? Promising findings show that both patient and donor-derived CAR-T suppress key inflammatory gene signatures in SLE, suggesting a molecular immune reset beyond clinical remission. #ACR26

Akhil Sood MD, MS
@AkhilSoodMD
Erosions and seronegative RA? Abstract 2932 found anti-MFN1 - IgG a/w with inc risk of radiographic erosions at baseline (OR 3.04) & 2 years (OR 3.24) + the adjusted model - IgA a/w erosive disease at baseline only; higher erosion score at baseline & 2 years @RheumNow #ACR26
Sadhak Sengupta
@sadhaksengupta
@Aclockworkolive @drdavidliew @NEJM @RheumNow Both rap-cel and zola-cel targets to keep the infusion material enriched in CCR7+CD27+ naive state, for which the ex vivo part of the expansion has to be stopped before the cells start differentiating. Longer the ex vivo culture, higher the percentage of differentiation.
Mrinalini Dey
@DrMiniDey
In 60 RA patients, grayscale ultrasound correlated with biopsy inflammation in early and refractory disease. Power Doppler correlated only in early RA. Biopsies with high ultrasound scores but little inflammation often showed scar tissue. #2934 @Rheumnow #ACR26
Mrinalini Dey
@DrMiniDey
Anti-mitofusin-1 IgG was found in 9.7% of 638 ESPOIR patients with early arthritis. In RF/ACPA-negative patients, positivity was linked to higher odds of erosions at 2 years (aOR 3.47; 95% CI 1.17-11.0). A potential marker of erosive seronegative RA. #2932 @Rheumnow #ACR26
Janet Pope
@Janetbirdope
#Efgartigimod #RCT in #inflammatory #myositis Combined efficacy of #dermatomyositis #IMNM All primary combined and component Endpts met Subsets favored #efgartigimod in both #DM & #IMNM 59% infection vs 48% PBO SIE low CK ☑️ #LB24 @ACRheum #ACR26 @RheumNow https://t.co/w7OSfAILLS
×